PMV Pharmaceuticals, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

PMVP$1.22-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · AccumulatedOther Comprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	(Loss) Income	Deficit	Equity
Balance at December 31, 2024	51,935,134	$—	$544,653	$139	$(368,712)	$176,080
Exercise of stock options	19,001	—	10	—	—	10
Stock-based compensation expense	—	—	1,508	—	—	1,508
Net loss	—	—	—	—	(17,436)	(17,436)
Unrealized loss on investments	—	—	—	(62)	—	(62)
Foreign currency translation gain	—	—	—	7	—	7
Balance at March 31, 2025	51,954,135	$—	$546,171	$84	$(386,148)	$160,107
Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units	1,039,103	—	103	—	—	103
Stock-based compensation expense	—	—	1,668	—	—	1,668
Net loss	—	—	—	—	(21,210)	(21,210)
Unrealized loss on investments	—	—	—	(61)	—	(61)
Foreign currency translation loss	—	—	—	(2)	—	(2)
Balance at June 30, 2025	52,993,238	$—	$547,942	$21	$(407,358)	$140,605
Stock-based compensation expense	—	—	1,383	—	—	1,383
Net loss	—	—	—	—	(21,059)	(21,059)
Unrealized gain on available-for-sale investments	—	—	—	69	—	69
Foreign currency translation gain	—	—	—	1	—	1
Balance at September 30, 2025	52,993,238	$—	$549,325	$91	$(428,417)	$120,999

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · AccumulatedOther Comprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	(Loss) Income	Deficit	Equity
Balance at December 31, 2025	53,331,766	$—	$551,082	$84	$(446,454)	$104,712
Stock-based compensation expense	—	—	1,392	—	—	1,392
Net loss	—	—	—	—	(18,038)	(18,038)
Unrealized loss on available-for-sale investments	—	—	—	(101)	—	(101)
Foreign currency translation gain	—	—	—	2	—	2
Balance at March 31, 2026	53,331,766	$—	$552,474	$(15)	$(464,492)	$87,967
Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units	128,666	—	143	—	—	143
Stock-based compensation expense	—	—	1,543	—	—	1,543
Net loss	—	—	—	—	(18,086)	(18,086)
Unrealized loss on investments	—	—	—	(67)	—	(67)
Balance at June 30, 2026	53,460,432	$—	$554,160	$(82)	$(482,578)	$71,500
Exercise of stock options, common stock issued under the 2020 ESPP, and release of vested restricted stock units	19,310	—	26	—	—	26
Issuance of common stock and Pre-Funded Warrants, net of issuance costs	22,055,000	—	18,423	—	—	18,423
Stock-based compensation expense	—	—	1,605	—	—	1,605
Net loss	—	—	—	—	(34,372)	(34,372)
Unrealized loss on available-for-sale investments	—	—	—	(76)	—	(76)
Foreign currency translation gain	—	—	—	2	—	2
Balance at September 30, 2026	75,534,742	$—	$574,214	$(156)	$(516,950)	$57,108

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.